Photo:
merzbranding.com
Aug 28, 2026, 16:44
HEMGENIX Supply Update for the Hemophilia B Community – National Bleeding Disorders Foundation
National Bleeding Disorders Foundation shared on LinkedIn:
”Treatment availability update for the hemophilia B community:
CSL Behring has shared an update regarding the availability of HEMGENIX (etranacogene dezaparvovec-drlb), its gene therapy for hemophilia B.
Following the temporary global stockout announced in March 2026, the company reports that it reestablished a limited supply in April and continues to actively manage existing supply.
Read the full update and learn more.”
Stay updated with Hemostasis Today.
-
Aug 28, 2026, 17:16ASH 2026 Guideline on ITP: Evolving Treatment Strategies
-
Aug 28, 2026, 16:39Maria Elisa Mancuso: Attending EHC 2026 Annual Conference in Istanbul
-
Aug 28, 2026, 16:25Manali Kakadia: Evaluation and Management of Recurrent Epistaxis
-
Aug 28, 2026, 16:18Navigating Higher Education with a Bleeding Disorder – Bleeding Disorders Council of California
-
Aug 28, 2026, 16:11Maia Meier: Reaching New Heights for Women With Inherited Bleeding Disorders
-
Aug 28, 2026, 15:10Ify Osunkwo: Strengthening Sickle Cell Care Systems at Global Conference in Nairobi
-
Aug 28, 2026, 15:08Muhammed Safvan: One Drop of Blood Can Tell a Story
-
Aug 28, 2026, 14:52Jessica Lee: Standing Together for Children and Families with Bleeding Disorders
-
Aug 28, 2026, 14:45Daisy Souster: A New Chapter in Bleeding Disorder Advocacy